Page last updated: 2024-10-22

ag-1296 and Leukemia, Promyelocytic, Acute

ag-1296 has been researched along with Leukemia, Promyelocytic, Acute in 1 studies

6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase

Leukemia, Promyelocytic, Acute: An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.

Research Excerpts

ExcerptRelevanceReference
"The standard treatment for acute promyelocytic leukemia (APL) involves differentiation therapy with retinoic acid (RA)."1.35Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells. ( Bunaciu, RP; Reiterer, G; Smith, JL; Yen, A, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Reiterer, G1
Bunaciu, RP1
Smith, JL1
Yen, A1

Other Studies

1 other study available for ag-1296 and Leukemia, Promyelocytic, Acute

ArticleYear
Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells.
    FEBS letters, 2008, Jul-23, Volume: 582, Issue:17

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD18 Antigens; Cell Different

2008